Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, Rishipathak D, Peng J, Şenbabaoǧlu Y, Modrusan Z, Keerthivasan S, Madireddi S, Chen YJ, Fraser EJ, Leng N, Hamidi H, Koeppen H, Ziai J, Hashimoto K, Fassò M, Williams P, McDermott DF, Rosenberg JE, Powles T, Emens LA, Hegde PS, Mellman I, Turley SJ, Wilson MS, Mariathasan S, Molinero L, Merchant M, West NR. Huseni MA, et al. Among authors: hashimoto k. Cell Rep Med. 2023 Jan 17;4(1):100878. doi: 10.1016/j.xcrm.2022.100878. Epub 2023 Jan 3. Cell Rep Med. 2023. PMID: 36599350 Free PMC article.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Yuen KC, et al. Among authors: hashimoto k. Nat Med. 2020 May;26(5):693-698. doi: 10.1038/s41591-020-0860-1. Epub 2020 May 11. Nat Med. 2020. PMID: 32405063 Free PMC article.
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Motzer RJ, et al. Among authors: hashimoto k. Cancer Cell. 2020 Dec 14;38(6):803-817.e4. doi: 10.1016/j.ccell.2020.10.011. Epub 2020 Nov 5. Cancer Cell. 2020. PMID: 33157048 Free PMC article.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Yuen KC, et al. Among authors: hashimoto k. Nat Med. 2021 Mar;27(3):560. doi: 10.1038/s41591-021-01246-4. Nat Med. 2021. PMID: 33547461 No abstract available.
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF. Powles T, et al. Among authors: hashimoto k. Eur Urol. 2021 May;79(5):665-673. doi: 10.1016/j.eururo.2021.01.003. Epub 2021 Mar 5. Eur Urol. 2021. PMID: 33678522 Free PMC article. Clinical Trial.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Pal SK, et al. Among authors: hashimoto k. BJU Int. 2020 Jul;126(1):73-82. doi: 10.1111/bju.15058. Epub 2020 Apr 24. BJU Int. 2020. PMID: 32233107 Free PMC article. Clinical Trial.
Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study.
WakasakiI T, Manako T, YasumatsuI R, Hara H, Toh S, Masuda M, YamauchiID M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. WakasakiI T, et al. Among authors: hashimoto k. PLoS One. 2024 May 9;19(5):e0303720. doi: 10.1371/journal.pone.0303720. eCollection 2024. PLoS One. 2024. PMID: 38722895 Free PMC article.
7,687 results